SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Zeller Bernward) "

Sökning: WFRF:(Zeller Bernward)

  • Resultat 1-10 av 47
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Wendtland Edslev, Pernille, et al. (författare)
  • Age and Prognosis in Pediatric AML
  • 2008
  • Ingår i: Blood. - 1528-0020 .- 0006-4971. ; 112:11
  • Konferensbidrag (refereegranskat)
  •  
2.
  • Abildgaard, Lotte, et al. (författare)
  • Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
  • 2006
  • Ingår i: Annals of hematology. - : Springer Science and Business Media LLC. - 0939-5555 .- 1432-0584. ; 85:5, s. 275-80
  • Tidskriftsartikel (refereegranskat)abstract
    • Children with Down syndrome (DS) and myeloid leukaemia have a significantly higher survival rate than other children, but they also experience considerable treatment-related toxicity. We analysed data on 56 children with DS who were treated on the Nordic Society for Paediatric Haematology and Oncology-acute myeloid leukaemia (NOPHO-AML)88 and NOPHO-AML93 protocols and reviewed the literature. In the dose-intensive NOPHO-AML88 protocol, 8 out of 15 patients (53%) experienced an event. In the less dose-intensive NOPHO-AML93 protocol, 7 out of 41 patients (17%) had an event. Therapy was reduced in 29 patients (52%) with in average 75% and 67% of the scheduled dose of anthracycline and cytarabine, respectively. Treatment-related death occurred in seven who all received full treatment. Relapse and resistant disease occurred at a similar rate in those receiving full and reduced treatment. Review of major series of myeloid leukaemia of DS showed no clear relationship between dose and survival; however, it appears that both a reduction in treatment dose and a less intensively timed treatment regimen improved the outcome. Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS.
  •  
3.
  • Abrahamsson, Jonas, 1954, et al. (författare)
  • Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia
  • 2018
  • Ingår i: Pediatric Blood & Cancer. - : John Wiley & Sons. - 1545-5009 .- 1545-5017. ; 65:9
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundChildren with acute myeloid leukemia (AML) treated similarly show different toxicity and leukemic responses. We investigated associations between neutrophil recovery time after the first induction course, infection and relapse in children treated according to NOPHO-AML 2004 and DB AML-01. ProcedureNewly diagnosed patients with AML with bone marrow blast<5% between day 15 after the start of the treatment and the start of second induction course, and in complete remission after the second induction course were included (n=279). Neutrophil recovery time was defined as the time from the start of the course to the last day with absolute neutrophil count<0.5x10(9)/l. Linear and Cox regressions were used to investigate associations. ResultsNeutrophil recovery time after the first induction course was positively associated with neutrophil recovery time after the remaining courses, and longer neutrophil recovery time (25 days) was associated with increased risk of grade 3-4 infections (hazard ratio 1.4, 95% confidence interval [CI], 1.1-1.8). Longer neutrophil recovery time after the first induction (>30 days) was associated with the increased risk of relapse (5-year cumulative incidence: 48% vs. 42%, hazard ratio 1.7, 95% CI, 1.1-2.6) for cases not treated with hematopoietic stem cell transplantation in first complete remission. ConclusionLonger neutrophil recovery time after the first induction course was associated with grade 3-4 infections and relapse. If confirmed, this knowledge could be incorporated into risk stratification strategies in pediatric AML.
  •  
4.
  • Abrahamsson, Jonas, 1954, et al. (författare)
  • Improved outcome after relapse in children with acute myeloid leukaemia.
  • 2007
  • Ingår i: British journal of haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 136:2, s. 229-236
  • Tidskriftsartikel (refereegranskat)abstract
    • In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.
  •  
5.
  •  
6.
  • Abrahamsson, Jonas, 1954, et al. (författare)
  • Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
  • 2019
  • Ingår i: Pediatric blood & cancer. - : Wiley. - 1545-5017 .- 1545-5009. ; 66:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Supportive-care use of granulocyte colony-stimulating factor (G-CSF) in pediatric acute myeloid leukemia (AML) remains controversial due to a theoretical increased risk of relapse and limited impact on neutropenic complications. We describe the use of G-CSF in patients treated according to NOPHO-AML 2004 and DB AML-01 and investigated associations with relapse.Patients diagnosed with de novo AML completing the first week of therapy and not treated with hematopoietic stem cell transplantation in the first complete remission were included (n=367). Information on G-CSF treatment after each course (yes/no) was registered prospectively in the study database and detailed information was gathered retrospectively from each center. Descriptive statistics were used to describe G-CSF use and Cox regression to assess the association between G-CSF and risk of relapse.G-CSF as supportive care was given to 128 (35%) patients after 268 (39%) courses, with a large variation between centers (0-93%). The use decreased with time-the country-adjusted odds ratio was 0.8/diagnostic year (95% confidence interval [CI] 0.7-0.9). The median daily dose was 5 μg/kg (range 3-12 μg/kg) and the median cumulative dose was 75 μg/kg (range 7-1460 μg/kg). Filgrastim was used in 82% of G-CSF administrations and infection was the indication in 44% of G-CSF administrations. G-CSF was associated with increased risk of relapse-the adjusted hazard ratio was 1.5 (95% CI 1.1-2.2).G-CSF as supportive care was used in a third of patients, and use decreased with time. Our results indicate that the use of G-CSF may be associated with an increased risk of relapse.
  •  
7.
  •  
8.
  • Arad-Cohen, Nira, et al. (författare)
  • Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium
  • 2022
  • Ingår i: Expert Review of Anticancer Therapy. - : Taylor & Francis Group. - 1473-7140 .- 1744-8328. ; 22:11, s. 1183-1196
  • Forskningsöversikt (refereegranskat)abstract
    • Introduction Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and acute and long-term cardiotoxicity. Despite this knowledge, there are no definite supportive care guidelines as to what the best approach is to manage or prevent these complications. Area covered The NOPHO-DB-SHIP (Nordic-Dutch-Belgian-Spain-Hong-Kong-Israel-Portugal) consortium, in preparation for a new trial in pediatric AML patients, had dedicated meetings for supportive care. In this review, the authors discuss the available data and outline recommendations for the management of children and adolescents with AML with an emphasis on hyperleukocytosis, tumor lysis syndrome, coagulation abnormalities and bleeding, infection, typhlitis, malnutrition, cardiotoxicity, and fertility preservation. Expert opinion Improved supportive care has significantly contributed to increased cure rates. Recommendations on supportive care are an essential part of treatment for this highly susceptible population and will further improve their outcome.
  •  
9.
  • Bager, Ninna, et al. (författare)
  • Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia : A NOPHO-DBH-AML study
  • 2018
  • Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 183:4, s. 618-628
  • Tidskriftsartikel (refereegranskat)abstract
    • Data on occurrence, genetic characteristics and prognostic impact of complex and monosomal karyotype (CK/MK) in children with acute myeloid leukaemia (AML) are scarce. We studied CK and MK in a large unselected cohort of childhood AML patients diagnosed and treated according to Nordic Society for Paediatric Haematology and Oncology (NOPHO)-AML protocols 1993-2015. In total, 800 patients with de novo AML were included. CK was found in 122 (15%) and MK in 41 (5%) patients. CK and MK patients were young (median age 2.1 and 3.3 years, respectively) and frequently had FAB M7 morphology (24% and 22%, respectively). Refractory disease was more common in MK patients (15% vs. 4%) and stem cell transplantation in first complete remission was more frequent (32% vs. 19%) compared with non-CK/non-MK patients. CK showed no association with refractory disease but was an independent predictor of an inferior event-free survival (EFS; hazard ratio [HR] 1.43, P = 0.03) and overall survival (OS; HR 1.48, P = 0.01). MK was associated with a poor EFS (HR 1.57, P = 0.03) but did not show an inferior OS compared to non-MK patients (HR 1.14, P = 0.62). In a large paediatric cohort, we characterized AML with non-recurrent abnormal karyotype and unravelled the adverse impact of CK and MK on prognosis.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 47
Typ av publikation
tidskriftsartikel (26)
konferensbidrag (14)
annan publikation (6)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (32)
övrigt vetenskapligt/konstnärligt (10)
Författare/redaktör
Zeller, Bernward (47)
Hasle, Henrik (38)
Jahnukainen, Kirsi (32)
Lausen, Birgitte (28)
Abrahamsson, Jonas, ... (25)
Palle, Josefine (23)
visa fler...
Jonsson, Olafur G. (21)
Forestier, Erik (21)
Abrahamsson, Jonas (20)
Ha, Shau-Yin (18)
Heldrup, Jesper (16)
Palle, Josefine, 196 ... (11)
Koskenvuo, Minna (8)
De Moerloose, Barbar ... (8)
Gustafsson, Göran (7)
Kjeldsen, Eigil (7)
Cavelier, Lucia (6)
Sundström, Christer (6)
Hovi, Liisa (6)
Jonmundsson, Gudmund ... (6)
Höglund, Martin (6)
Holmfeldt, Linda (6)
Noren-Nyström, Ulrik ... (6)
Clausen, Niels (5)
Asdahl, Peter H. (4)
Kaspers, Gertjan J. ... (4)
Saks, Kadri (4)
Skaftason, Aron (4)
Jonsson, OG (3)
Palmqvist, Lars, 196 ... (3)
Komorowski, Jan (3)
Jonsson, Olafur Gisl ... (3)
Hovland, Randi (3)
Eriksson, Anna (3)
Staffas, Anna, 1982 (3)
Kovalova, Zhanna (3)
Reinhardt, Dirk (3)
Norgren, Nina (3)
Kaspers, GJ (2)
Rosenquist, Richard (2)
Kanduri, Meena, 1974 (2)
Schmiegelow, Kjeld (2)
Taskinen, Mervi (2)
Ehrencrona, Hans (2)
Bager, Ninna (2)
Sandahl, Julie D. (2)
Juul-Dam, KL (2)
Sandahl, JD (2)
Mayrhofer, Markus, 1 ... (2)
Locatelli, Franco (2)
visa färre...
Lärosäte
Uppsala universitet (27)
Göteborgs universitet (26)
Umeå universitet (16)
Lunds universitet (11)
Karolinska Institutet (11)
Språk
Engelska (47)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (44)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy